APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumor Necrosis Factor Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Tumor Necrosis Factor Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025191 pages

Choose your research edition.

Industry ResearchTumor Necrosis Factor Inhibitors Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Necrosis Factor Inhibitors Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Tumor Necrosis Factor Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Necrosis Factor Inhibitors Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Necrosis Factor Inhibitors Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Tumor Necrosis Factor Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Tumor Necrosis Factor Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tumor Necrosis Factor Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumor Necrosis Factor Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Tumor Necrosis Factor Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tumor Necrosis Factor Inhibitors include Janssen Biotech, GlaxoSmithKline, Momenta Pharmaceuticals, MedImmune, LG Life Sciences, LEO Pharma, Intas Pharmaceuticals, HanAll Biopharma and EPIRUS Biopharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tumor Necrosis Factor Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tumor Necrosis Factor Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tumor Necrosis Factor Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tumor Necrosis Factor Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Tumor Necrosis Factor Inhibitors Segment by Company

Janssen Biotech

GlaxoSmithKline

Momenta Pharmaceuticals

MedImmune

LG Life Sciences

LEO Pharma

Intas Pharmaceuticals

HanAll Biopharma

EPIRUS Biopharmaceuticals

Dexa Medica

CASI Pharmaceuticals

Bionovis

Tumor Necrosis Factor Inhibitors Segment by Type

Enbrel

Remicade

Humira

Others

Tumor Necrosis Factor Inhibitors Segment by Application

Ischemic Stroke

Parkinson's Diseases

Multiple Sclerosis

Alzheimer's Diseases

Others

Tumor Necrosis Factor Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tumor Necrosis Factor Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Tumor Necrosis Factor Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Tumor Necrosis Factor Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Tumor Necrosis Factor Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Tumor Necrosis Factor Inhibitors Industry Trends Table 2. Tumor Necrosis Factor Inhibitors Industry Drivers Table 3. Tumor Necrosis Factor Inhibitors Industry Opportunities and Challenges Table 4. Tumor Necrosis Factor Inhibitors Industry Restraints Table 5. Global Tumor Necrosis Factor Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Tumor Necrosis Factor Inhibitors Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Manufacturers Table 9. Global Tumor Necrosis Factor Inhibitors Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Tumor Necrosis Factor Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Tumor Necrosis Factor Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Tumor Necrosis Factor Inhibitors Manufacturers, Product Type & Application Table 13. Global Tumor Necrosis Factor Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Tumor Necrosis Factor Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Enbrel Table 17. Major Manufacturers of Remicade Table 18. Major Manufacturers of Humira Table 19. Major Manufacturers of Others Table 20. Global Tumor Necrosis Factor Inhibitors Sales by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Tumor Necrosis Factor Inhibitors Sales by Type (2021-2026) & (k units) Table 22. Global Tumor Necrosis Factor Inhibitors Sales by Type (2027-2032) & (k units) Table 23. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2021-2026) Table 24. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2027-2032) Table 25. Global Tumor Necrosis Factor Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global Tumor Necrosis Factor Inhibitors Revenue by Type (2021-2026) & (k units) Table 27. Global Tumor Necrosis Factor Inhibitors Revenue by Type (2027-2032) & (k units) Table 28. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2021-2026) Table 29. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Ischemic Stroke Table 31. Major Manufacturers of Parkinson's Diseases Table 32. Major Manufacturers of Multiple Sclerosis Table 33. Major Manufacturers of Alzheimer's Diseases Table 34. Major Manufacturers of Others Table 35. Global Tumor Necrosis Factor Inhibitors Sales by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Tumor Necrosis Factor Inhibitors Sales by Application (2021-2026) & (k units) Table 37. Global Tumor Necrosis Factor Inhibitors Sales by Application (2027-2032) & (k units) Table 38. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2021-2026) Table 39. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2027-2032) Table 40. Global Tumor Necrosis Factor Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 41. Global Tumor Necrosis Factor Inhibitors Revenue by Application (2021-2026) & (k units) Table 42. Global Tumor Necrosis Factor Inhibitors Revenue by Application (2027-2032) & (k units) Table 43. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2021-2026) Table 44. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2027-2032) Table 45. Global Tumor Necrosis Factor Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Tumor Necrosis Factor Inhibitors Sales by Region (2021-2026) & (k units) Table 47. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Region (2021-2026) Table 48. Global Tumor Necrosis Factor Inhibitors Sales Forecasted by Region (2027-2032) & (k units) Table 49. Global Tumor Necrosis Factor Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Tumor Necrosis Factor Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. North America Tumor Necrosis Factor Inhibitors Sales by Country (2021-2026) & (k units) Table 52. North America Tumor Necrosis Factor Inhibitors Sales by Country (2027-2032) & (k units) Table 53. Europe Tumor Necrosis Factor Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Europe Tumor Necrosis Factor Inhibitors Sales by Country (2021-2026) & (k units) Table 55. Europe Tumor Necrosis Factor Inhibitors Sales by Country (2027-2032) & (k units) Table 56. Asia Pacific Tumor Necrosis Factor Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Country (2021-2026) & (k units) Table 58. Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Country (2027-2032) & (k units) Table 59. South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 60. South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Country (2021-2026) & (k units) Table 61. South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Country (2027-2032) & (k units) Table 62. Global Tumor Necrosis Factor Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Tumor Necrosis Factor Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Tumor Necrosis Factor Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Region (2021-2026) Table 66. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Region (2027-2032) Table 67. Janssen Biotech Company Information Table 68. Janssen Biotech Business Overview Table 69. Janssen Biotech Tumor Necrosis Factor Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Janssen Biotech Tumor Necrosis Factor Inhibitors Product Portfolio Table 71. Janssen Biotech Recent Development Table 72. GlaxoSmithKline Company Information Table 73. GlaxoSmithKline Business Overview Table 74. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Product Portfolio Table 76. GlaxoSmithKline Recent Development Table 77. Momenta Pharmaceuticals Company Information Table 78. Momenta Pharmaceuticals Business Overview Table 79. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio Table 81. Momenta Pharmaceuticals Recent Development Table 82. MedImmune Company Information Table 83. MedImmune Business Overview Table 84. MedImmune Tumor Necrosis Factor Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. MedImmune Tumor Necrosis Factor Inhibitors Product Portfolio Table 86. MedImmune Recent Development Table 87. LG Life Sciences Company Information Table 88. LG Life Sciences Business Overview Table 89. LG Life Sciences Tumor Necrosis Factor Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. LG Life Sciences Tumor Necrosis Factor Inhibitors Product Portfolio Table 91. LG Life Sciences Recent Development Table 92. LEO Pharma Company Information Table 93. LEO Pharma Business Overview Table 94. LEO Pharma Tumor Necrosis Factor Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. LEO Pharma Tumor Necrosis Factor Inhibitors Product Portfolio Table 96. LEO Pharma Recent Development Table 97. Intas Pharmaceuticals Company Information Table 98. Intas Pharmaceuticals Business Overview Table 99. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio Table 101. Intas Pharmaceuticals Recent Development Table 102. HanAll Biopharma Company Information Table 103. HanAll Biopharma Business Overview Table 104. HanAll Biopharma Tumor Necrosis Factor Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. HanAll Biopharma Tumor Necrosis Factor Inhibitors Product Portfolio Table 106. HanAll Biopharma Recent Development Table 107. EPIRUS Biopharmaceuticals Company Information Table 108. EPIRUS Biopharmaceuticals Business Overview Table 109. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio Table 111. EPIRUS Biopharmaceuticals Recent Development Table 112. Dexa Medica Company Information Table 113. Dexa Medica Business Overview Table 114. Dexa Medica Tumor Necrosis Factor Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Dexa Medica Tumor Necrosis Factor Inhibitors Product Portfolio Table 116. Dexa Medica Recent Development Table 117. CASI Pharmaceuticals Company Information Table 118. CASI Pharmaceuticals Business Overview Table 119. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio Table 121. CASI Pharmaceuticals Recent Development Table 122. Bionovis Company Information Table 123. Bionovis Business Overview Table 124. Bionovis Tumor Necrosis Factor Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Bionovis Tumor Necrosis Factor Inhibitors Product Portfolio Table 126. Bionovis Recent Development Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Tumor Necrosis Factor Inhibitors Distributors List Table 130. Tumor Necrosis Factor Inhibitors Customers List Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Tumor Necrosis Factor Inhibitors Product Image Figure 2. Global Tumor Necrosis Factor Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tumor Necrosis Factor Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Tumor Necrosis Factor Inhibitors Sales (2021-2032) & (k units) Figure 5. Global Tumor Necrosis Factor Inhibitors Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Tumor Necrosis Factor Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Enbrel Image Figure 9. Remicade Image Figure 10. Humira Image Figure 11. Others Image Figure 12. Global Tumor Necrosis Factor Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Tumor Necrosis Factor Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2021-2032) Figure 15. Global Tumor Necrosis Factor Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Tumor Necrosis Factor Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2021-2032) Figure 18. Ischemic Stroke Image Figure 19. Parkinson's Diseases Image Figure 20. Multiple Sclerosis Image Figure 21. Alzheimer's Diseases Image Figure 22. Others Image Figure 23. Global Tumor Necrosis Factor Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Tumor Necrosis Factor Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2021-2032) Figure 26. Global Tumor Necrosis Factor Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Tumor Necrosis Factor Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2021-2032) Figure 29. North America Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 30. North America Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2021-2032) Figure 31. U.S. Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 32. Canada Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 33. Mexico Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2021-2032) Figure 36. Germany Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 37. France Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 38. U.K. Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 39. Italy Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 40. Netherlands Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2021-2032) Figure 43. China Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 44. Japan Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 45. South Korea Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 46. Southeast Asia Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 47. India Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 48. Australia Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2021-2032) Figure 51. Brazil Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 52. South Africa Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 53. Saudi Arabia Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 54. Turkey Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 55. Argentina Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 56. UAE Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 57. Egypt Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 58. Chile Tumor Necrosis Factor Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 59. Global Tumor Necrosis Factor Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Tumor Necrosis Factor Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. North America Tumor Necrosis Factor Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Tumor Necrosis Factor Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. Europe Tumor Necrosis Factor Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Tumor Necrosis Factor Inhibitors Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Tumor Necrosis Factor Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Tumor Necrosis Factor Inhibitors Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Tumor Necrosis Factor Inhibitors Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Enbrel
  • Remicade
  • Humira
  • Others
Applications
  • Ischemic Stroke
  • Parkinson's Diseases
  • Multiple Sclerosis
  • Alzheimer's Diseases
  • Others
Companies covered
  • Janssen Biotech
  • GlaxoSmithKline
  • Momenta Pharmaceuticals
  • MedImmune
  • LG Life Sciences
  • LEO Pharma
  • Intas Pharmaceuticals
  • HanAll Biopharma
  • EPIRUS Biopharmaceuticals
  • Dexa Medica
  • CASI Pharmaceuticals
  • Bionovis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tumor Necrosis Factor Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tumor Necrosis Factor Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Tumor Necrosis Factor Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Tumor Necrosis Factor Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Tumor Necrosis Factor Inhibitors Market Dynamics
  1. 2.1 Tumor Necrosis Factor Inhibitors Industry Trends
  2. 2.2 Tumor Necrosis Factor Inhibitors Industry Drivers
  3. 2.3 Tumor Necrosis Factor Inhibitors Industry Opportunities and Challenges
  4. 2.4 Tumor Necrosis Factor Inhibitors Industry Restraints
3 Tumor Necrosis Factor Inhibitors Market by Manufacturers
  1. 3.1 Global Tumor Necrosis Factor Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Tumor Necrosis Factor Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Tumor Necrosis Factor Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Tumor Necrosis Factor Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Tumor Necrosis Factor Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Tumor Necrosis Factor Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Tumor Necrosis Factor Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Tumor Necrosis Factor Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Tumor Necrosis Factor Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Tumor Necrosis Factor Inhibitors Tier 1, Tier 2, and Tier 3
4 Tumor Necrosis Factor Inhibitors Market by Type
  1. 4.1 Tumor Necrosis Factor Inhibitors Type Introduction
  2. 4.1.1 Enbrel
  3. 4.1.2 Remicade
  4. 4.1.3 Humira
  5. 4.1.4 Others
  6. 4.2 Global Tumor Necrosis Factor Inhibitors Sales by Type
  7. 4.2.1 Global Tumor Necrosis Factor Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Tumor Necrosis Factor Inhibitors Sales by Type (2021-2032)
  9. 4.2.3 Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2021-2032)
  10. 4.3 Global Tumor Necrosis Factor Inhibitors Revenue by Type
  11. 4.3.1 Global Tumor Necrosis Factor Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Tumor Necrosis Factor Inhibitors Revenue by Type (2021-2032)
  13. 4.3.3 Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2021-2032)
5 Tumor Necrosis Factor Inhibitors Market by Application
  1. 5.1 Tumor Necrosis Factor Inhibitors Application Introduction
  2. 5.1.1 Ischemic Stroke
  3. 5.1.2 Parkinson's Diseases
  4. 5.1.3 Multiple Sclerosis
  5. 5.1.4 Alzheimer's Diseases
  6. 5.1.5 Others
  7. 5.2 Global Tumor Necrosis Factor Inhibitors Sales by Application
  8. 5.2.1 Global Tumor Necrosis Factor Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Tumor Necrosis Factor Inhibitors Sales by Application (2021-2032)
  10. 5.2.3 Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2021-2032)
  11. 5.3 Global Tumor Necrosis Factor Inhibitors Revenue by Application
  12. 5.3.1 Global Tumor Necrosis Factor Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Tumor Necrosis Factor Inhibitors Revenue by Application (2021-2032)
  14. 5.3.3 Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Tumor Necrosis Factor Inhibitors Sales by Region
  1. 6.1 Global Tumor Necrosis Factor Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tumor Necrosis Factor Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Tumor Necrosis Factor Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Tumor Necrosis Factor Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tumor Necrosis Factor Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Tumor Necrosis Factor Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Tumor Necrosis Factor Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Tumor Necrosis Factor Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Tumor Necrosis Factor Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Tumor Necrosis Factor Inhibitors Revenue by Region
  1. 7.1 Global Tumor Necrosis Factor Inhibitors Revenue by Region
  2. 7.1.1 Global Tumor Necrosis Factor Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Tumor Necrosis Factor Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Tumor Necrosis Factor Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Tumor Necrosis Factor Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Tumor Necrosis Factor Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Tumor Necrosis Factor Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Tumor Necrosis Factor Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Tumor Necrosis Factor Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Tumor Necrosis Factor Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Janssen Biotech
  2. 8.1.1 Janssen Biotech Company Information
  3. 8.1.2 Janssen Biotech Business Overview
  4. 8.1.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Product Portfolio
  6. 8.1.5 Janssen Biotech Recent Developments
  7. 8.2 GlaxoSmithKline
  8. 8.2.1 GlaxoSmithKline Company Information
  9. 8.2.2 GlaxoSmithKline Business Overview
  10. 8.2.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Product Portfolio
  12. 8.2.5 GlaxoSmithKline Recent Developments
  13. 8.3 Momenta Pharmaceuticals
  14. 8.3.1 Momenta Pharmaceuticals Company Information
  15. 8.3.2 Momenta Pharmaceuticals Business Overview
  16. 8.3.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio
  18. 8.3.5 Momenta Pharmaceuticals Recent Developments
  19. 8.4 MedImmune
  20. 8.4.1 MedImmune Company Information
  21. 8.4.2 MedImmune Business Overview
  22. 8.4.3 MedImmune Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 MedImmune Tumor Necrosis Factor Inhibitors Product Portfolio
  24. 8.4.5 MedImmune Recent Developments
  25. 8.5 LG Life Sciences
  26. 8.5.1 LG Life Sciences Company Information
  27. 8.5.2 LG Life Sciences Business Overview
  28. 8.5.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 LG Life Sciences Tumor Necrosis Factor Inhibitors Product Portfolio
  30. 8.5.5 LG Life Sciences Recent Developments
  31. 8.6 LEO Pharma
  32. 8.6.1 LEO Pharma Company Information
  33. 8.6.2 LEO Pharma Business Overview
  34. 8.6.3 LEO Pharma Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 LEO Pharma Tumor Necrosis Factor Inhibitors Product Portfolio
  36. 8.6.5 LEO Pharma Recent Developments
  37. 8.7 Intas Pharmaceuticals
  38. 8.7.1 Intas Pharmaceuticals Company Information
  39. 8.7.2 Intas Pharmaceuticals Business Overview
  40. 8.7.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio
  42. 8.7.5 Intas Pharmaceuticals Recent Developments
  43. 8.8 HanAll Biopharma
  44. 8.8.1 HanAll Biopharma Company Information
  45. 8.8.2 HanAll Biopharma Business Overview
  46. 8.8.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Product Portfolio
  48. 8.8.5 HanAll Biopharma Recent Developments
  49. 8.9 EPIRUS Biopharmaceuticals
  50. 8.9.1 EPIRUS Biopharmaceuticals Company Information
  51. 8.9.2 EPIRUS Biopharmaceuticals Business Overview
  52. 8.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio
  54. 8.9.5 EPIRUS Biopharmaceuticals Recent Developments
  55. 8.10 Dexa Medica
  56. 8.10.1 Dexa Medica Company Information
  57. 8.10.2 Dexa Medica Business Overview
  58. 8.10.3 Dexa Medica Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Dexa Medica Tumor Necrosis Factor Inhibitors Product Portfolio
  60. 8.10.5 Dexa Medica Recent Developments
  61. 8.11 CASI Pharmaceuticals
  62. 8.11.1 CASI Pharmaceuticals Company Information
  63. 8.11.2 CASI Pharmaceuticals Business Overview
  64. 8.11.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Portfolio
  66. 8.11.5 CASI Pharmaceuticals Recent Developments
  67. 8.12 Bionovis
  68. 8.12.1 Bionovis Company Information
  69. 8.12.2 Bionovis Business Overview
  70. 8.12.3 Bionovis Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bionovis Tumor Necrosis Factor Inhibitors Product Portfolio
  72. 8.12.5 Bionovis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tumor Necrosis Factor Inhibitors Value Chain Analysis
  2. 9.1.1 Tumor Necrosis Factor Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tumor Necrosis Factor Inhibitors Production Mode & Process
  6. 9.2 Tumor Necrosis Factor Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tumor Necrosis Factor Inhibitors Distributors
  9. 9.2.3 Tumor Necrosis Factor Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst